免疫调节方法在管理COVID-19中的肺炎:双刃剑
Geetika Verma1, Manish Dhawan2,3, AbdulRahman A Saied4
1Department of Experimental Medicine and Biotechnology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Immunity, inflammation and disease
|September 29, 2023
概括
本综述探讨了免疫调节策略,以管理COVID-19引起的肺炎. 这些方法旨在抵消细胞因子风暴,减少严重的呼吸系统疾病,可能挽救生命.
科学领域:
- 免疫学 免疫学 免疫学
- 病毒学 病毒学
- 肺部病理学 肺部病理学
背景情况:
- 由SARS-CoV-2引起的COVID-19在很大程度上准了肺部,而诸如Delta和Omicron这样的变种会造成严重损害.
- 感染SARS-CoV-2引发了细胞因子风暴,释放了促炎媒介 (IL-6,IL-1β,TNF-α),导致肺炎,ARDS和肺炎.
- 接种疫苗的人群中突破性感染突出了有效治疗干预措施的必要性.
研究的目的:
- 审查有希望的免疫调节方法来管理COVID-19患者的肺炎.
- 为了确定严重的COVID-19病例的潜在未来治疗选择.
- 讨论应对细胞因子风暴有害影响的策略.
主要方法:
- 关于免疫调节策略的文献综述.
- 在SARS-CoV-2感染中分析细胞因子风暴机制.
- 对免疫调节疗法的临床试验数据的评估.
主要成果:
- 通过细胞因子的释放,SARS-CoV-2诱导显著的肺炎.
- 细胞因子风暴是严重的COVID-19,ARDS和肺炎的一个关键因素.
- 免疫调节方法正在研究以减轻肺炎并改善结果.
结论:
- 免疫调节策略在控制COVID-19引起的肺炎方面表现有前途.
- 这些方法在未来可能会提供挽救生命的治疗选择.
- 需要仔细考虑风险,例如免疫抑制引起的二次感染.
相关概念视频
Drugs Used in Lower Respiratory Disorders: Overview
474
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
474
COPD: Management Using Bronchodilators and Corticosteroids
236
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
236
Asthma: Pathogenesis and Management
433
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
433
Chronic Obstructive Pulmonary Disease-V: Management
2.6K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.6K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
326
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
326
Antiasthma Drugs: Leukotriene Modifiers
338
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
338


